ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.10%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.30%, a 72.00% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.50%, a 127.27% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.10%, a 35.29% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.10%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.30%, a 10.26% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.90%, a 178.57% increase from fiscal 2021.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.40%, a 17.65% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.10% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 4.10% 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | 4.10% 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | 4.30% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 4.30% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 4.30% 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | 4.30% 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 3.90% 10-K · filed 2025-03-03 | |||
| 2022-09-30 | 3.00% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | 2.50% 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | 1.40% 10-K · filed 2024-02-29 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | 1.10% 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | 1.70% 10-K · filed 2023-02-14 | |||
| 2020-09-30 | 1.70% 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | 1.70% 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | 1.70% 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | 2.50% 10-K · filed 2022-02-15 | |||
| 2019-09-30 | 2.50% 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | 2.50% 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | 3.00% 10-K · filed 2021-02-24 | |||
| 2017-12-31 | 2.40% 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |